In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA Sponsors Should Ask DMF Holders About 'Hidden Facilities'

Generics Firms Urged To Check For Facilities Not Listed In Applications

Executive Summary

FDA says 16% of ANDAs have an issue with "hidden facilities" that are listed in drug master files but not the ANDAs they are linked with; industry official offers some tips to bridge this communications gap with DMF holders.

You may also be interested in...



New Exposure Limits For Excipients Applauded While Loss Of Old Potency Limits Bemoaned

The US FDA has launched the second phase of an effort to improve its inactive ingredients database by replacing confusing potency amounts with maximum daily exposure limits, a change sought by generic drug and excipient manufactures.

US FDA Allows Simpler Approach To Expire Dating When Repackaging Drugs Into Unit Doses

The US FDA will not enforce expiration dating requirements for unit-dose repackaging if repackagers follow an alternative approach outlined in final guidance.

DSCSA Pilot Used Blockchain To Trace Drug Through 'Last Mile' of Supply Chain

A blockchain application for mobile devices was successfully piloted to conduct real-time tracking of a high-cost drug through the “last mile” of the supply chain to the point of dispensing. Such a tool can be useful for manufacturers in tracing their products through the supply chain and complying with a forthcoming mandate of the US FDA Drug Supply Chain Security Act (DSCSA).

Topics

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel